Summary of Q1 2014
Strategic development
* Bioporto has signed an agreement with Abbott for cross-licenses to both parties’ respective IP rights within NGAL.
* BioPorto and Phadia has reached a settlement in the case before the Supreme Court regarding the invalidation of Phadia’s patent, which specifies the use of HNL (another designation for NGAL) as a diagnostic marker for human diseases. Along with the settlement, BioPorto receives a license for Phadia’s patents regarding NGAL worldwide.
Help employers find you! Check out all the jobs and post your resume.
